Serum immunoreactive prolyl hydroxylase in inflammatory rheumatic diseases

EEVA-RIITTA KUUTTI-SAVOLAINEN, KARI I. KIVIRIKKO, AND OSSI LAITINEN

From the 1Department of Medical Biochemistry, University of Oulu, Oulu, Finland, the 2Third Department of Medicine, University of Helsinki, Helsinki, Finland, and the 3Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden

SUMMARY Serum immunoreactive prolyl hydroxylase protein (S-IRPH) was measured in 56 patients with inflammatory rheumatic diseases, and the values were compared with those in 32 control subjects. S-IRPH was above the 95% confidence limit of the controls in about 70% of the patients with active systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Reiter’s syndrome, Sjögren’s syndrome, polyarteritis nodosa, or polymyositis. Raised values were observed in about half of the patients with an erythrocyte sedimentation rate (ESR) of 21–50 and in about 90% of those with ESR of over 50, whereas only about 10% of the patients with an inactive disease had an S-IRPH concentration exceeding this limit. Only 1 out of 8 patients with active ankylosing spondylitis had a raised S-IRPH value. The results support previous data indicating that significant changes in collagen metabolism occur in active connective tissue diseases. Assays of S-IRPH might be of some value in assessing the activity of these diseases and in monitoring the treatment provided.

A number of observations indicate that definite changes in collagen metabolism occur in connective tissue diseases. Studies on collagen solubility,1–5 the rate of incorporation of radioactive proline into skin collagen in vitro,6–8 and the pattern of collagen cross-links9 are all consistent with an increased rate of formation of this protein in some patients with connective tissue diseases. The activities of two intracellular enzymes of collagen biosynthesis, prolyl hydroxylase10–12 and galactosylhydroxylsyl glucosyltransferase,13 are similarly elevated in the skin in some of these diseases, and an increased activity of the former enzyme has been reported in rheumatoid synovial tissue.14 The rate of collagen degradation is likewise altered. An increased collagenase activity is found in the synovial tissue15–17 and synovial fluid18–19 of patients with rheumatoid arthritis, while the urinary excretion of hydroxyproline, which reflects the turnover of collagen in a number of tissues, is elevated in patients with most connective tissue diseases (reviews20–21).

The biosynthesis of collagen involves many unique post-translational enzyme reactions, and these have been the subject of intensive investigation during recent years (reviews22–24). The hydroxylation of prolyl residues has an important role among these reactions, as the newly-synthesised polypeptide chains do not form triple-helical, functional molecules if the chains are deficient in hydroxyproline (see above reviews). Measurements of prolyl hydroxylase activity in a number of experimental and clinical states have indicated that this enzyme activity is usually increased in conditions associated with an enhanced rate of collagen formation (review25). Prolyl hydroxylase activity is also found in human serum,26–27 though the activity is quite low and has failed to be detected in some instances.28 More recently the presence of immunoreactive prolyl hydroxylation protein (S–IRPH) has been demonstrated in human serum,29–31 most of this protein corresponding in size to the inactive monomers of the active enzyme tetramer.30 So far increases in S–IRPH have been found particularly in patients with diseases associated with an increased prolyl hydroxylase activity in the liver, and it has been suggested that assays of this serum protein may give useful information on actual hepatic collagen synthesis.31–37
S–IRPH has also been measured in a number of patients with various dermatological diseases limited to the skin and has been found to be within the normal limits in essentially all of them, even though many of the patients had increased prolyl hydroxylase activity in the skin lesions.\(^2\) By contrast a group of 7 patients having active systemic connective tissue diseases with skin affections, including systemic lupus erythematosus, scleroderma, and dermatomyositis, showed elevated S–IRPH in 4 cases, though the enzyme activity in the skin was elevated in only 1.\(^2\) These observations suggested a study on changes in S–IRPH using a larger series of patients with connective tissue diseases.

**Patients and methods**

**Patients**

Sera from 56 patients with the following rheumatic diseases were examined: 20 with systemic lupus erythematosus (SLE), 16 with rheumatoid arthritis (RA), 10 with ankylosing spondylitis (AS), 5 with scleroderma (SCL), 2 with Reiter’s syndrome, 1 with Sjögren’s syndrome, 1 with polyarteritis nodosa, and 1 with polymyositis. The distribution of the patients by age and sex is given in Table 1. The patients with SLE had signs of multiple systemic involvement of the disease, positive tests for the LE phenomenon, and antinuclear antibodies, and they all fulfilled the preliminary criteria of the ARA for a diagnosis of SLE.\(^3\) RA similarly fulfilled the ARA criteria,\(^4\) and AS the diagnostic criteria for this disease.\(^5\) The SCL patients displayed characteristic clinical symptoms, and the diagnosis was substantiated by positive skin biopsies and radiological evidence of oesophageal and/or skeletal involvement. The patients with Reiter’s syndrome, Sjögren’s syndrome, polyarteritis nodosa, and polymyositis were all typical cases with an active disease. The patients were diagnosed at the Department of Rheumatology, Karolinska Hospital, Stockholm, and the series included patients with greatly varying disease activities, mostly receiving some antirheumatic medication. The S–IRPH values were compared with those in 32 apparently healthy controls, as used previously.\(^6\) The control sera were stored frozen at \(-20^\circ\text{C}\) and reassayed together with the sera from the patients.

**Measurement of Serum Immunoreactive Prolyl Hydroxylase**

The concentration of S–IRPH was measured by a direct radioimmunoassay based on the displacement of radioactively labelled prolyl hydroxylase from its antibody by nonlabelled enzyme and the subsequent precipitation of the enzyme-antibody complex by a cellulose-bound second antibody.\(^7\) The assay measures both the active enzyme tetramers and the inactive monomers, the degree of displacement of the labelled enzyme being similar regardless of whether the enzyme is in the tetramer or monomer form.\(^7\) Pure human prolyl hydroxylase\(^8\) was used to produce the antiserum and to prepare the labelled enzyme, and was also used as the enzyme standard. The sera were stored frozen at \(-20^\circ\text{C}\), with no thawing, for up to 4 years until assayed. It has previously been reported that sera can be stored at \(-20^\circ\text{C}\) for at least 2 years with no loss in S–IRPH,\(^9\) and additional control experiments on 10 sera which had been analysed for S–IRPH and then stored at \(-20^\circ\text{C}\) for 4 years indicated no loss in this protein with either high or low original concentrations.

**Results**

The mean S–IRPH concentration was significantly raised in the patients with SLE, RA, AS, and SCL, and individual values in the patients with other diseases included in these series were also high, with the exception of 1 case of Reiter’s syndrome (Table 1). As the disease activities varied greatly

---

**Table 1**  
**Serum immunoreactive prolyl hydroxylase (S–IRPH) in controls and in patients with inflammatory rheumatic diseases**

<table>
<thead>
<tr>
<th>Group</th>
<th>(n)</th>
<th>Sex</th>
<th>Age* (years)</th>
<th>S–IRPH* (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Controls</td>
<td>32</td>
<td>10</td>
<td>32 ± 14</td>
<td>1 ± 24 ± 0-17</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>20</td>
<td>3</td>
<td>17</td>
<td>38 ± 16</td>
</tr>
<tr>
<td>Arthritis</td>
<td>16</td>
<td>8</td>
<td>8</td>
<td>55 ± 17</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>41 ± 13</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>46 ± 8</td>
</tr>
<tr>
<td>Reiter’s syndrome</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>31, 56</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>38</td>
</tr>
<tr>
<td>Polyarteritis nodosa</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>44</td>
</tr>
<tr>
<td>Polymyositis</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>63</td>
</tr>
</tbody>
</table>

*Mean ± SD; in Reiter’s syndrome individual values.
†Statistical significance of the difference in S–IRPH when compared with the controls (Student’s \(t\) test); ND = not determined.
between individual patients, the series was divided into 3 subgroups on the basis of the erythrocyte sedimentation rate (ESR): subgroup 0, consisting of patients with inactive disease, ESR less than 21 (12 cases, ESR 9 ± 6, mean ± SD); subgroup 1, active disease, ESR 21–50 (22 cases, ESR 35 ± 7); and subgroup 2, very active disease, ESR more than 50 (22 cases, ESR 85 ± 28). The other laboratory data and clinical symptoms were consistent with this division.

In the patients with SLE and RA about half of the S-IRPH values in subgroup 1 (4 out of 10 with SLE and 2 out of 4 with RA) and 80–90% in subgroup 2 (5 out of 6 with SLE and 7 out of 8 with RA) were above the normal upper limit 1·58 mg/l, defined as the mean ± 2 SD of the controls (Fig. 1), whereas none of the 8 values in cases of inactive SLE and RA was above the limit. All 3 patients with very active SCL and all with very active Reiter’s syndrome, polyarteritis nodosa, or polymyositis likewise had S-IRPH values exceeding the normal upper limit, whereas the patient with Reiter’s syndrome belonging to subgroup 1 had a value below the limit. One of the 2 values for inactive SCL was elevated. An extremely high value was found in the 1 active case of Sjögren’s syndrome, which had an ESR of 41 on the day of the study, although much higher values were frequently recorded. The patients with AS differed clearly from the others in that only 1 out of 6 S-IRPH values in subgroup 1 and neither of the 2 in subgroup 2 exceeded the normal upper limit (Fig. 1), even though the mean ESR values for AS cases in subgroups 1 and 2 were essentially identical with those in the corresponding subgroups of the whole patient series.

There was a highly significant correlation between S-IRPH and ESR in SLE (r = 0·687, P < 0·001), a weak correlation in RA (r = 0·559, P < 0·05) and a significant correlation in the whole patient series excluding AS (r = 0·400, P < 0·01), whereas no correlation was found in AS (r = 0·230).

Discussion

The results indicate that S-IRPH is above the normal upper limit in about 70% of all patients with the active diseases studied here, excluding AS, but is below this limit in about 90% of those with an inactive disease. High values were found in about half of the cases in subgroup 1 (ESR 21–50) and in about 90% in subgroup 2 (ESR > 50). These findings agree with those reported previously in patients having active systemic connective tissue diseases with skin manifestations (see above), in that out of these 7 patients, all of whom had an ESR of 21–50, 4 had an elevated S-IRPH. These data thus provide a further parameter pointing to distinct changes in collagen metabolism in connective tissue diseases.

High S-IRPH concentrations have previously been reported in patients with increased prolyl hydroxylase activity in the liver, including cancer with liver metastases,31,37 and in a few patients having malignant diseases without liver involvement, whereas essentially all the patients with dermatological diseases having an increased prolyl hydroxylase activity in the skin lesions had normal S-IRPH concentrations.38 In liver diseases a significant correlation was found between prolyl hydroxylase activity in the hepatic biopsy specimens and S-IRPH concentration.37 It thus seems that an elevated prolyl hydroxylase activity in the liver alone can be
associated with increased S-IRPH whereas an increased activity in other instances may not have an appreciable effect on the S-IRPH concentration unless the change is quite marked or is present in a number of connective tissues. In this connection it is of interest that, although the mean S-IRPH was elevated in AS, only 1 out of 8 patients with an active or very active disease had a value exceeding the normal upper limit.

The present data on S-IRPH differ from those previously reported for serum prolyl hydroxylase activity in that increases in the latter were found in certain diseases affecting the liver, especially hepatocellular carcinoma, whereas a group of 32 patients with various connective tissue diseases included only 1 value in a case of scleroderma which was above the mean ± 2 SD of controls. Several reasons can be found for this difference. Firstly, the assays of serum prolyl hydroxylase activity measure only the active enzyme tetramers, whereas the radioimmunoassay used here also measures the inactive enzyme protein, more than 90% of S-IRPH being the inactive form. Secondly, the assay of the serum enzyme activity is relatively insensitive, and the normal values lie just within the limits of detection, resulting in an artificially high scatter; and thirdly, the serum also contains inhibitors of prolyl hydroxylase activity. An additional problem in assays of serum prolyl hydroxylase activity is the rapid inactivation of this enzyme, whereas S-IRPH is very stable.

The correlation between S-IRPH and ESR in the whole series of patients apart from those with AS, and the distribution of raised S-IRPH values between the subgroups 0, 1, and 2 indicate that the elevation of S-IRPH correlates with the disease activity. The ESR is not an optimal indicator of disease activity, however, and hence it is not surprising to find some disagreement between S-IRPH and ESR in a number of individual values. Assays of S-IRPH can be carried out quite easily provided that pure human prolyl hydroxylase and its antisemur are available, and they require less than 50 μl of serum. It would thus seem that assays of S-IRPH could be of some value in assessing the activity of connective tissue diseases and in monitoring their treatment. More extensive studies are required, however, to elucidate the possible usefulness of S-IRPH determinations for these purposes.

The authors are grateful to Professor Börje Ohagen and Docent Ragnhild Gullberg, of the Department of Rheumatology, Karolinska Hospital, Stockholm, for permission to obtain the sera, and Mrs Ritva Pihkakoski, Mrs Laina Göransson, and Mrs Irene Kronmyr for their expert technical assistance. This work was supported in part by grants from the Medical Research Council of the Academy of Finland.

References
Serum immuno-reactive prolyl hydroxylase in inflammatory rheumatic diseases


Serum immunoreactive prolyl hydroxylase in inflammatory rheumatic diseases.
E R Kuutti-Savolainen, K I Kivirikko and O Laitinen

doi: 10.1136/ard.39.3.217

Updated information and services can be found at:
http://ard.bmj.com/content/39/3/217

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/